Skip to content
Medical Health Aged Care, National News Current Affairs

PRESS CALL for 7.30am Monday 7th August

Australian Dental Association < 1 mins read

PRESS CALL for 7.30am, Monday 7 August

 

Event: Launch of the new Oral Health Messages for Australia – A National Consensus Statement

The 11-point oral health charter includes new recommendations and approaches for Australian healthcare providers, consumers and policymakers on vaping, flossing, alcohol consumption, mouthguard use and the age a child should have their first visit to the dentist.

Who: Launched by Assistant Minister for Health and Aged Care the Hon. Ged Kearney MP, Chair of the Senate Select Committee into Dental Services Senator Jordon Steele-John, and Australian Dental Association Federal President Dr Stephen Liew. Also expected to attend are Federal MPs and representatives from other peak health bodies.

 

When: 7.30am to 9.30am, Monday 7th August, for the start of Dental Health

Week (7-13th), the Australian Dental Association’s (ADA) annual oral health campaign.

 

Where: Parliament House, Canberra - the Dame Dorothy Tangney Alcove. Breakfast available.

 

For more information / media RSVP: ADA Media Advisor Jenny Barlass

0484 869 086 or [email protected].

 

Media

More from this category

  • Medical Health Aged Care
  • 08/12/2025
  • 17:10
Galderma Group AG

Galderma Welcomes Increased Equity Investment From L’Oréal

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.